A randomized, double-blind study of a combination of amlodipine and irbesartan in patients with essential hypertension who insufficiently responded to amlodipine once daily
Phase 2
- Conditions
- Hypertension
- Registration Number
- JPRN-jRCT2080221076
- Lead Sponsor
- Dainippon Sumitomo Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with essential hypertension who meet one of the following criteria
a) Patients who are taking antihypertensive drugs
b) Patients who are not taking any antihypertensive drugs and whose seated systolic blood pressure (SBP) is >=160 mmHg or whose diastolic blood pressure (DBP) is >=100 mmHg
Exclusion Criteria
Patients with renal, hepatic or heart desease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy: Change in trough BP from baseline
- Secondary Outcome Measures
Name Time Method Efficacy: Populations of patients whose trough BPs successively reached the target level